Cost-outcome of Hepatocellular Carcinoma Screening at Roi-Et Hospital

Main Article Content

Wittaya Roongjangram
Nilawan Upakdee


Introduction: Hepatocellular carcinoma (HCC) in Thailand was one of leading cause of death. Currently, the guideline for diagnosis and treatment of HCC have advanced. The mortality rate was high because most patients received medical examination when cancer entered late-stage. The screening was more important in finding new cases. Therefore, the study of cost of screening for HCC at the population level will be useful for economic evaluation. Objective: To determine cost and outcome of HCC screening at Roi-Et Hospital. Methods: This is the descriptive study of the HCC screening at Roi-Et Hospital between February 2011 and November 2013. This study measured general characteristics, direct medical costs, outcome of screening and one-way sensitivity analysis. Results: There were 973 positive HBsAg patients received HCC screening with aged 44.10 ± 11.87 years and most of them are domiciled in Roi-Et Province. 120 patients were detected as positive HBeAg and 4 patients had positive hepatitis C antibody. When the screening was finished, found 9 early-stage HCC patients, 1 late-stage HCC patient and 5 cholangiocarcinoma patients. Total of medical cost was 4,776,045 baht and average medical cost was 4,908.58 baht/visit. Conclusion: Cost of treatment of HCC and cholangiocarcinoma (CCA) is higher than cost of HCC screening. Therefore, considering HCC screening at the population level will lead to early-stage HCC finding that can reduce mortality rate and cost of HCC treatment.


Download data is not yet available.

Article Details

Pharmaceutical Practice


Amarapurkar D, Han KH, Chan HLY, et al. Application of surveillance programs for hepatocellular carcinoma in the Asia–Pacific Region. J Gastroenterol Hepatol 2009; 24(6): 955-961.

Bureau of Policy and Strategy, Office of the Permanent Secretary. Health Statistics 2014. Bangkok: Printing Press of the War Veterans Organization of Thailand under Royal Patronage of His Majesty the King; 2015.

Chaiwerawattana A, Sukarayodhin S, Koraluck A, Kuhaprema T, editors. Clinical practice guidelines of screening and treatment for hepatocellular carcinoma and cholangiocarcinoma in Thailand. Bangkok: National Office of Buddhism Printing House; 2011.

Cucchetti A, Cescon M, Erroi V, et al. Cost-effectiveness of liver cancer screening. Best Pract Res Clin Gastroenterol 2013; 27(6): 961-972.

Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW, editors. 4th edition. Method for the economic evaluation of health programmes. Oxford: Oxford University Press; 1997.

Health Administration Division. Public health service rate of Ministry of Public Health. Nonthaburi: Printing House of The Agriculture Co-operative Federation of Thailand; 2017.

Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am 2015; 24(1): 1-17.

Riewpaiboon A, editor. Standard cost lists for health technology assessment. Bangkok: Thana Press; 2011.

Sangmala P, Chaikledkaew U, Tanwandee T, et al. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients. Asian Pac J Cancer Prev 2013; 15(20): 8993-9004.

Sawatdimongkol S, editor. Annual report 2014 - Bureau of Non Communicable Disease. Bangkok: Printing Press of the War Veterans Organization of Thailand under Royal Patronage of His Majesty the King; 2014.

Srisubat A, Chaiwerawattana A, Tunsakul S, et al. Cost-effectiveness of alpha-fetoprotein and liver ultrasound for hepatocellular carcinoma screening in patients with chronic hepatitis B. Bull Dept Med Serv 2012; 37(2): 81-9.

Thai Association for the Study of the Liver. Clinical practice guidelines for patients with hepatocellular carcinoma in Thailand, 2015. Nonthaburi: Parbpim Printing; 2015.

The Comptroller General’s Department. Public health service rate of The Comptroller General’s Department. Bangkok: Ministry of finance; 2017.

Tomuen C, editor. Roi-Et Hospital based cancer registry 2014. Roi-Et: Tunjai Printing 7-9; 2016.

Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65(2): 87-108.

Wanich N, Vilaichone R, Chotivitayatarakorn P, et al. High prevalence of hepatocellular carcinoma in patients with chronic hepatitis B infection in Thailand. Asian Pac J Cancer Prev 2016; 17(6): 2857.